A role for sigma receptors in stimulant self administration and addiction

Pharmaceuticals

Volumn 4, Issue 6, 2011, Pages 880-914

  Katz, Jonathan L ^a   Su, Tsung Ping ^a   Hiranita, Takato ^a   Hayashi, Teruo ^a   Tanda, Gianluigi ^a   Kopajtic, Theresa ^a   Tsai, Shang Yi ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Cocaine; Drug abuse; Reinforcing effects; Self administration; Sigma receptors

Indexed keywords

1 CYCLOPROPYLMETHYL 4 [2 (4 FLUOROPHENYL) 2 OXOETHYL]PIPERIDINE; 1 PHENYLCYCLOHEXANECARBOXYLIC ACID 2 MORPHOLINOETHYL ESTER; 2 [4 METHOXY 3 (2 PHENYLETHOXY)PHENYL] N,N DIPROPYLETHYLAMINE; 4 AMINOBUTYRIC ACID; ACETYLCHOLINE; CHAPERONE; CLOZAPINE; COCAINE; CUTAMESINE; DIZOCILPINE; DOPAMINE; GLUTAMIC ACID; HALOPERIDOL; IGMESINE; METHAMPHETAMINE; N ALLYLNORMETAZOCINE; N [2 (3,4 DICHLOROPHENYL)ETHYL] N METHYL 2 (1 PYRROLIDINYL)ETHYLAMINE; NALOXONE; NEUROTRANSMITTER; NORADRENALIN; OPIATE AGONIST; OPIATE ANTAGONIST; PENTAZOCINE; PREGNENOLONE; PREGNENOLONE SULFATE; SEROTONIN; SIGMA OPIATE 1 RECEPTOR; SIGMA OPIATE RECEPTOR; SIGMA RECEPTOR LIGAND; UNCLASSIFIED DRUG;

ARTICLE; CELL STRESS; CELLULAR DISTRIBUTION; DISCRIMINATIVE STIMULUS; DRUG DEPENDENCE; DRUG RECEPTOR BINDING; DRUG SELF ADMINISTRATION; DRUG SENSITIZATION; GENE CONTROL; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; LOCOMOTION; MOLECULAR DYNAMICS; NEUROTOXICITY; NEUROTRANSMISSION; NONHUMAN; NUCLEUS ACCUMBENS; PLACE PREFERENCE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION;

EID: 79959956710     PISSN: None     EISSN: 14248247     Source Type: Journal    
DOI: 10.3390/ph4060880     Document Type: Article

References (165)

1. Matsumoto, R.R.; Liu, Y.; Lerner, M.; Howard, E.W.; Brackett, D.J. Sigma receptors: Potential medications development target for anti-cocaine agents. Eur. J. Pharmacol. 2003, 469, 1-12.
2. Guitart, X.; Codony, X.; Monroy, X. Sigma receptors: Biology and therapeutic potential. Psychopharmacology (Berl) 2004, 174, 301-319.
3. Maurice, T.; Romieu, P. Involvement of the sigma1 receptor in the appetitive effects of cocaine. Pharmacopsychiatry 2004, 37(Suppl), S198-S207.
4. Leonard, B.E. Sigma receptors and sigma ligands: background to a pharmacological enigma. Pharmacopsychiatry 2004, 37(Suppl), S166-S170.
5. Skuza, G.; Wedzony, K. Behavioral pharmacology of sigma-ligands. Pharmacopsychiatry 2004, 37(Suppl), S183-S188.
6. Martin, W.R.; Eades, C.G.; Thompson, J.A.; Huppler, R.E.; Gilbert, P.E. The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J. Pharmacol. Exp. Ther. 1976, 197, 517-532.
7. Vaupel, D.B. Naltrexone fails to antagonize the sigma effects of PCP and SKF 10,047 in the dog. Eur. J. Pharmacol. 1983, 92, 269-274.
8. Quirion, R.; Hammer, R.P., Jr.; Herkenham, M.; Pert, C.B. Phencyclidine (angel dust)/sigma opiate receptor: Visualization by tritium-sensitive film. Proc. Natl. Acad. Sci. USA 1981, 78, 5881-5885.
9. Holtzman, S.G. Phencyclidine-like discriminative stimulus properties of opioids in the squirrel monkey. Psychopharmacology (Berl) 1982, 77, 295-300.
10. Wong, E.H.; Kemp, J.A.; Priestley, T.; Knight, A.R.; Woodruff, G.N.; Iversen, L.L. The anticonvulsant MK-801 is a potent N-methyl-D-aspartate antagonist. Proc. Natl. Acad. Sci. USA 1986, 83, 7104-7108.
11. Weber, E.; Sonders, M.; Quarum, M.; McLean, S.; Pou, S.; Keana, J.F. 1,3-Di(2-[5-3H]tolyl)guanidine: A selective ligand that labels sigma-type receptors for psychotomimetic opiates and antipsychotic drugs. Proc. Natl. Acad. Sci. US A 1986, 83, 8784-8788.
12. Matsumoto, R.R.; Bowen, W.D.; Su, T.P. Sigma Receptors: Chemistry, Cell Biology and Clinical Implications. Springer Science + Business Media, LLC: New York, NY, USA, 2007.
13. Maurice, T.; Su, T.P. The pharmacology of sigma-1 receptors. Pharmacol. Ther. 2009, 124, 1 95-206.
14. Hayashi, T.; Su, T.P. Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca(2+) signaling and cell survival. Cell 2007, 131, 596-610.
15. Pal, A.; Chu, U.B.; Ramachandran, S.; Grawoig, D.; Guo, L.W.; Hajipour, A.R.; Ruoho, A.E. Juxtaposition of the steroid binding domain-like I and II regions constitutes a ligand binding site in the sigma-1 receptor. J. Biol. Chem. 2008, 283, 19646-19656.
16. Su, T.P.; Hayashi, T.; Maurice, T.; Buch, S.; Ruoho, A.E. The sigma-1 receptor chaperone as an inter-organelle signaling modulator. Trends Pharmacol. Sci. 2010, 31, 557-566.
17. Hanner, M.; Moebius, F.F.; Flandorfer, A.; Knaus, H.G.; Striessnig, J.; Kempner, E.; Glossmann, H. Purification, molecular cloning, and expression of the mammalian sigma1-binding site. Proc. Natl. Acad. Sci. USA 1996, 93, 8072-8077.
18. Hayashi, T.; Tsai, S.Y.; Mori, T.; Fujimoto, M.; Su, T.P. Targeting ligand-operated chaperone sigma-1 receptors in the treatment of neuropsychiatric disorders. Expert Opin. Ther. Targets 2011, 15, 557-577.
19. Ha, Y.; Dun, Y.; Thangaraju, M.; Duplantier, J.; Dong, Z.; Liu, K.; Ganapathy, V.; Smith, S.B. Sigma receptor 1 modulates endoplasmic reticulum stress in retinal neurons. Invest. Ophthalmol. Vis. Sci. 2011, 52, 527-540.
20. Martin, W.R. Pharmacology of opioids. Pharmacol. Rev. 1983, 35, 283-323.
21. Itzhak, Y. Multiple affinity binding states of the sigma receptor: Effect of GTP-binding protein-modifying agents. Mol. Pharmacol. 1989, 36, 512-517.
22. Hayashi, T.; Rizzuto, R.; Hajnoczky, G.; Su, T.P. MAM: More than just a housekeeper. Trends Cell Biol. 2009, 19, 81-88.
23. Rizzuto, R.; Pinton, P.; Brini, M.; Chiesa, A.; Filippin, L.; Pozzan, T. Mitochondria as biosensors of calcium microdomains. Cell Calcium 1999, 26, 193-199.
24. Mavlyutov, T.A.; Epstein, M.L.; Andersen, K.A.; Ziskind-Conhaim, L.; Ruoho, A.E. The sigma-1 receptor is enriched in postsynaptic sites of C-terminals in mouse motoneurons. An anatomical and behavioral study. Neuroscience 2010, 167, 247-255.
25. Aydar, E.; Palmer, C.P.; Klyachko, V.A.; Jackson, M.B. The sigma receptor as a ligand-regulated auxiliary potassium channel subunit. Neuron 2002, 34, 399-410.
26. Fontanilla, D.; Johannessen, M.; Hajipour, A.R.; Cozzi, N.V.; Jackson, M.B.; Ruoho, A.E. The hallucinogen N,N-dimethyltryptamine (DMT) is an endogenous sigma-1 receptor regulator. Science 2009, 323, 934-937.
27. Kim, F.J.; Kovalyshyn, I.; Burgman, M.; Neilan, C.; Chien, C.C.; Pasternak, G.W. Sigma 1 receptor modulation of G-protein-coupled receptor signaling: Potentiation of opioid transduction independent from receptor binding. Mol. Pharmacol. 2010, 77, 695-703.
28. Navarro, G.; Moreno, E.; Aymerich, M.; Marcellino, D.; McCormick, P.J.; Mallol, J.; Cortes, A.; Casado, V.; Canela, E.I.; Ortiz, J., et al. Direct involvement of sigma-1 receptors in the dopamine D1 receptor-mediated effects of cocaine. Proc. Natl. Acad. Sci. USA 2010, 107, 18676-18681.
29. Martina, M.; Turcotte, M.E.; Halman, S.; Bergeron, R. The sigma-1 receptor modulates NMDA receptor synaptic transmission and plasticity via SK channels in rat hippocampus. J. Physiol. 2007, 578, 143-157.
30. Morin-Surun, M.P.; Collin, T.; Denavit-Saubie, M.; Baulieu, E.E.; Monnet, F.P. Intracellular sigma1 receptor modulates phospholipase C and protein kinase C activities in the brainstem. Proc. Natl. Acad. Sci. USA 1999, 96, 8196-8199.
31. Hayashi, T.; Su, T.P. Intracellular dynamics of sigma-1 receptors (sigma(1) binding sites) in NG108-15 cells. J. Pharmacol. Exp. Ther. 2003, 306, 726-733.
32. Hayashi, T.; Fujimoto, M. Detergent-resistant microdomains determine the localization of sigma-1 receptors to the endoplasmic reticulum-mitochondria junction. Mol. Pharmacol. 2010, 77, 517-528.
33. Hayashi, T.; Su, T.P. Subcellular Localization and Intracellular Dynamics of Sigma-1 Receptors. In Sigma Receptors: Chemistry, Cell Biology and Clinical Implications; Matsumoto, R.R.; Bowen, W.D.; Su, T.-P.; Eds; Springer: New York, NY, USA, 2007; pp. 151-164.
34. Hayashi, T.; Su, T.P. Sigma-1 receptors (sigma(1) binding sites) form raft-like microdomains and target lipid droplets on the endoplasmic reticulum: Roles in endoplasmic reticulum lipid compartmentalization and export. J. Pharmacol. Exp. Ther. 2003, 306, 718-725.
35. Palmer, C.P.; Mahen, R.; Schnell, E.; Djamgoz, M.B.; Aydar, E. Sigma-1 receptors bind cholesterol and remodel lipid rafts in breast cancer cell lines. Cancer Res. 2007, 67, 11166-11175.
36. Sun, F.C.; Wei, S.; Li, C.W.; Chang, Y.S.; Chao, C.C.; Lai, Y.K. Localization of GRP78 to mitochondria under the unfolded protein response. Biochem. J. 2006, 396, 31-39.
37. Johnson, S.; Michalak, M.; Opas, M.; Eggleton, P. The ins and outs of calreticulin: From the ER lumen to the extracellular space. Trends Cell Biol. 2001, 11, 122-129.
38. Crofts, A.J.; Leborgne-Castel, N.; Pesca, M.; Vitale, A.; Denecke, J. BiP and calreticulin form an abundant complex that is independent of endoplasmic reticulum stress. Plant Cell 1998, 10, 813-824.
39. Sharma, P.; Ignatchenko, V.; Grace, K.; Ursprung, C.; Kislinger, T.; Gramolini, A.O. Endoplasmic reticulum protein targeting of phospholamban: A common role for an N-terminal di-arginine motif in ER retention? PLoS One 2010, 5, e11496.
40. Yang, W.; Zheng, C.; Song, Q.; Yang, X.; Qiu, S.; Liu, C.; Chen, Z.; Duan, S.; Luo, J. A three amino acid tail following the TM4 region of the N-methyl-D-aspartate receptor (NR) 2 subunits is sufficient to overcome endoplasmic reticulum retention of NR1-1a subunit. J. Biol. Chem. 2007, 282, 9269-9278.
41. Schroder, M.; Kaufman, R.J. The mammalian unfolded protein response. Annu. Rev. Biochem. 2005, 74, 739-789.
42. Fujimoto, M.; Hayashi, T.; Urfer, R.; Mita, S.; Su, T.-P. Sigma-1 receptor agonist cutamesine enhances the secretion of brain-derived neurotrophic factor from neuroblastoma cells. Soc. Neurosci. Abst. 2010, 136.1/D33.
43. Sprong, H.; van der Sluijs, P.; van Meer, G. How proteins move lipids and lipids move proteins. Nat. Rev. Mol. Cell Biol. 2001, 2, 504-513.
44. Takebayashi, M.; Hayashi, T.; Su, T.P. Sigma-1 receptors potentiate epidermal growth factor signaling towards neuritogenesis in PC12 cells: Potential relation to lipid raft reconstitution. Synapse 2004, 53, 90-103.
45. Hayashi, T.; Su, T.P. The potential role of sigma-1 receptors in lipid transport and lipid raft reconstitution in the brain: Implication for drug abuse. Life Sci. 2005, 77, 1612-1624.
46. Aridor, M.; Guzik, A.K.; Bielli, A.; Fish, K.N. Endoplasmic reticulum export site formation and function in dendrites. J. Neurosci. 2004, 24, 3770-3776.
47. Mu, Y.; Otsuka, T.; Horton, A.C.; Scott, D.B.; Ehlers, M.D. Activity-dependent mRNA splicing controls ER export and synaptic delivery of NMDA receptors. Neuron 2003, 40, 581-594.
48. Takebayashi, M.; Hayashi, T.; Su, T.P. Nerve growth factor-induced neurite sprouting in PC12 cells involves sigma-1 receptors: Implications for antidepressants. J. Pharmacol. Exp. Ther. 2002, 303, 1227-1237.
49. Nishimura, T.; Ishima, T.; Iyo, M.; Hashimoto, K. Potentiation of nerve growth factor-induced neurite outgrowth by fluvoxamine: Role of sigma-1 receptors, IP3 receptors and cellular signaling pathways. PLoS One 2008, 3, e2558.
50. Tsai, S.Y.; Hayashi, T.; Harvey, B.K.; Wang, Y.; Wu, W.W.; Shen, R.F.; Zhang, Y.; Becker, K.G.; Hoffer, B.J.; Su, T.P. Sigma-1 receptors regulate hippocampal dendritic spine formation via a free radical-sensitive mechanism involving Rac1xGTP pathway. Proc. Natl. Acad. Sci. USA 2009, 106, 22468-22473.
51. Tsai, S.Y.; Hayashi, T.; Zhang, Y.; Becker, K.G.; Su, T.-P. Insights to the Sigma-1 receptor chaperone's cellular functions: A microarray report. Soc. Neurosci. Abstr. 2010, 136, 136.21/E11.
52. Walker, J.M.; Bowen, W.D.; Walker, F.O.; Matsumoto, R.R.; de Costa, B.; Rice, K.C. Sigma receptors: Biology and function. Pharmacol. Rev. 1990, 42, 355-402.
53. de Costa, B.R.; Bowen, W.D.; Hellewell, S.B.; Walker, J.M.; Thurkauf, A.; Jacobson, A.E.; Rice, K.C. Synthesis and evaluation of optically pure [3H]-(+)-pentazocine, a highly potent and selective radioligand for sigma receptors. FEBS Lett. 1989, 251, 53-58.
54. Bowen, W.D.; Tolentino, P.J.; Kirschner, B.N.; Varghese, P.; de Costa, B.R.; Rice, K.C. Sigma receptors and signal transduction: Negative modulation of signaling through phosphoinositide-linked receptor systems. NIDA Res. Monogr. 1993, 133, 69-93.
55. Matsumoto, R.R.; Pouw, B.; Mack, A.L.; Daniels, A.; Coop, A. Effects of UMB24 and (+/-)-SM 21, putative sigma2-preferring antagonists, on behavioral toxic and stimulant effects of cocaine in mice. Pharmacol. Biochem. Behav. 2007, 86, 86-91.
56. Garcés-Ramírez, L.; Green, J.; Hiranita, T.; Kopajtic, T.; Mereu, M.; Thomas, A.; Mesangeau, C.; Narayanan, S.; McCurdy, C.; Katz, J., et al. Sigma receptor agonists: Receptor binding and effects on mesolimbic dopamine neurotransmission assessed by microdialysis in rats. Biol. Psychiatry 2011, 69, 208-217.
57. Su, T.P. Sigma receptors. Putative links between nervous, endocrine and immune systems. Eur. J. Biochem. 1991, 200, 633-642.
58. Booth, R.G.; Wyrick, S.D.; Baldessarini, R.J.; Kula, N.S.; Myers, A.M.; Mailman, R.B. New sigma-like receptor recognized by novel phenylaminotetralins: Ligand binding and functional studies. Mol. Pharmacol. 1993, 44, 1232-1239.
59. Enomoto, R.; Ogita, K.; Yoneda, Y. Multiplicity of [3H]1,3-di-o-tolylguanidine binding sites with low affinity for haloperidol in rat brain. Biol. Pharm. Bull. 1993, 16, 989-996.
60. Vilner, B.J.; John, C.S.; Bowen, W.D. Sigma-1 and sigma-2 receptors are expressed in a wide variety of human and rodent tumor cell lines. Cancer Res. 1995, 55, 408-413.
61. Gundlach, A.L.; Largent, B.L.; Snyder, S.H. Autoradiographic localization of sigma receptor binding sites in guinea pig and rat central nervous system with (+)3H-3-(3-hydroxyphenyl)-N-(1-propyl)piperidine. J. Neurosci. 1986, 6, 1757-1770.
62. Gonzalez-Alvear, G.M.; Werling, L.L. Regulation of [3H]dopamine release from rat striatal slices by sigma receptor ligands. J. Pharmacol. Exp. Ther. 1994, 271, 212-219.
63. Imperato, A.; Tanda, G.; Frau, R.; di Chiara, G. Pharmacological profile of dopamine receptor agonists as studied by brain dialysis in behaving rats. J. Pharmacol. Exp. Ther. 1988, 245, 257-264.
64. Kanzaki, A.; Okumura, K.; Ujike, H.; Tsuchida, K.; Akiyama, K.; Otsuki, S. BMY-14802 reverses the reduction of striatal dopamine release induced by (+)-3-[3-hydroxyphenyl]-N-(1-propyl)piperidine. J. Neural. Transm. Gen. Sect. 1992, 90, 137-144.
65. Gudelsky, G.A. Effects of sigma receptor ligands on the extracellular concentration of dopamine in the striatum and prefrontal cortex of the rat. Eur. J. Pharmacol. 1995, 286, 223-228.
66. Gudelsky, G.A. Biphasic effect of sigma receptor ligands on the extracellular concentration of dopamine in the striatum of the rat. J. Neural. Transm. 1999, 106, 849-856.
67. Moison, D.; de Deurwaerdere, P.; Cagnotto, A.; Marrazzo, A.; Prezzavento, O.; Ronsisvalle, G.; Mennini, T.; Spampinato, U. Intrastriatal administration of sigma ligands inhibits basal dopamine release in vivo. Neuropharmacology 2003, 45, 945-953.
68. Kobayashi, T.; Matsuno, K.; Murai, M.; Mita, S. Sigma 1 receptor subtype is involved in the facilitation of cortical dopaminergic transmission in the rat brain. Neurochem. Res. 1997, 22, 1105-1109.
69. Minabe, Y.; Matsuno, K.; Ashby, C.R., Jr. Acute and chronic administration of the selective sigma1 receptor agonist SA4503 significantly alters the activity of midbrain dopamine neurons in rats: An in vivo electrophysiological study. Synapse 1999, 33, 129-140.
70. Hiranita, T.; Soto, P.L.; Tanda, G.; Katz, J.L. Reinforcing effects of sigma-receptor agonists in rats trained to self-administer cocaine. J. Pharmacol. Exp. Ther. 2010, 332, 515-524.
71. Pontieri, F.E.; Tanda, G.; di Chiara, G. Intravenous cocaine, morphine, and amphetamine preferentially increase extracellular dopamine in the shell as compared with the core of the rat nucleus accumbens. Proc. Natl. Acad. Sci. USA 1995, 92, 12304-12308.
72. Pontieri, F.E.; Tanda, G.; Orzi, F.; di Chiara, G. Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs. Nature 1996, 382, 255-257.
73. Tanda, G.; Pontieri, F.E.; di Chiara, G. Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. Science 1997, 276, 2048-2050.
74. Kalivas, P.W. The glutamate homeostasis hypothesis of addiction. Nat. Rev. Neurosci. 2009, 10, 561-572.
75. Bowers, M.S.; Chen, B.T.; Bonci, A. AMPA receptor synaptic plasticity induced by psychostimulants: The past, present, and therapeutic future. Neuron 2010, 67, 11-24.
76. Reissner, K.J.; Kalivas, P.W. Using glutamate homeostasis as a target for treating addictive disorders. Behav. Pharmacol. 2010, 21, 514-522.
77. Meyer, D.A.; Carta, M.; Partridge, L.D.; Covey, D.F.; Valenzuela, C.F. Neurosteroids enhance spontaneous glutamate release in hippocampal neurons. Possible role of metabotropic sigma1-like receptors. J. Biol. Chem. 2002, 277, 28725-28732.
78. Dong, L.Y.; Cheng, Z.X.; Fu, Y.M.; Wang, Z.M.; Zhu, Y.H.; Sun, J.L.; Dong, Y.; Zheng, P. Neurosteroid dehydroepiandrosterone sulfate enhances spontaneous glutamate release in rat prelimbic cortex through activation of dopamine D1 and sigma-1 receptor. Neuropharmacology 2007, 52, 966-974.
79. Schiess, A.R.; Partridge, L.D. Pregnenolone sulfate acts through a G-protein-coupled sigma1-like receptor to enhance short term facilitation in adult hippocampal neurons. Eur. J. Pharmacol. 2005, 518, 22-29.
80. Lhullier, F.L.; Nicolaidis, R.; Riera, N.G.; Cipriani, F.; Junqueira, D.; Dahm, K.C.; Brusque, A.M.; Souza, D.O. Dehydroepiandrosterone increases synaptosomal glutamate release and improves the performance in inhibitory avoidance task. Pharmacol. Biochem. Behav. 2004, 77, 601-606.
81. Chen, L.; Dai, X.N.; Sokabe, M. Chronic administration of dehydroepiandrosterone sulfate (DHEAS) primes for facilitated induction of long-term potentiation via sigma 1 (sigma1) receptor: Optical imaging study in rat hippocampal slices. Neuropharmacology 2006, 50, 380-392.
82. Li, Z.; Zhou, R.; Cui, S.; Xie, G.; Cai, W.; Sokabe, M.; Chen, L. Dehydroepiandrosterone sulfate prevents ischemia-induced impairment of long-term potentiation in rat hippocampal CA1 by up-regulating tyrosine phosphorylation of NMDA receptor. Neuropharmacology 2006, 51, 958-966.
83. Chen, B.T.; Bowers, M.S.; Martin, M.; Hopf, F.W.; Guillory, A.M.; Carelli, R.M.; Chou, J.K.; Bonci, A. Cocaine but not natural reward self-administration nor passive cocaine infusion produces persistent LTP in the VTA. Neuron 2008, 59, 288-297.
84. Russo, S.J.; Mazei-Robison, M.S.; Ables, J.L.; Nestler, E.J. Neurotrophic factors and structural plasticity in addiction. Neuropharmacology 2009, 56(Suppl), 73-82.
85. Ghitza, U.E.; Zhai, H.; Wu, P.; Airavaara, M.; Shaham, Y.; Lu, L. Role of BDNF and GDNF in drug reward and relapse: A review. Neurosci. Biobehav. Rev. 2010, 35, 157-171.
86. McGinty, J.F.; Whitfield, T.W., Jr.; Berglind, W.J. Brain-derived neurotrophic factor and cocaine addiction. Brain Res. 2010, 1314, 183-193.
87. Yagasaki, Y.; Numakawa, T.; Kumamaru, E.; Hayashi, T.; Su, T.P.; Kunugi, H. Chronic antidepressants potentiate via sigma-1 receptors the brain-derived neurotrophic factor-induced signaling for glutamate release. J. Biol. Chem. 2006, 281, 12941-12949.
88. Maurice, T.; Phan, V.L.; Privat, A. The anti-amnesic effects of sigma1 ([sigma]1) receptor agonists confirmed by in vivo antisense strategy in the mouse. Brain Res. 2001, 898, 113-121.
89. Sofuoglu, M. Cognitive enhancement as a pharmacotherapy target for stimulant addiction. Addiction 2010, 105, 38-48.
90. Junien, J.L.; Roman, F.J.; Brunelle, G.; Pascaud, X. JO1784, a novel sigma ligand, potentiates [3H]acetylcholine release from rat hippocampal slices. Eur. J. Pharmacol. 1991, 200, 343-345.
91. Matsuno, K.; Matsunaga, K.; Senda, T.; Mita, S. Increase in extracellular acetylcholine level by sigma ligands in rat frontal cortex. J. Pharmacol. Exp. Ther. 1993, 265, 851-859.
92. Matsuno, K.; Senda, T.; Kobayashi, T.; Mita, S. Involvement of sigma 1 receptor in (+)-N-allylnormetazocine-stimulated hippocampal cholinergic functions in rats. Brain Res. 1995, 690, 200-206.
93. Kobayashi, T.; Matsuno, K.; Mita, S. Regional differences of the effect of sigma receptor ligands on the acetylcholine release in the rat brain. J. Neural. Transm. 1996, 103, 661-669.
94. Kobayashi, T.; Matsuno, K.; Nakata, K.; Mita, S. Enhancement of acetylcholine release by SA4503, a novel sigma 1 receptor agonist, in the rat brain. J. Pharmacol. Exp. Ther. 1996, 279, 106-113.
95. Matsuno, K.; Senda, T.; Kobayashi, T.; Okamoto, K.; Nakata, K.; Mita, S. SA4503, a novel cognitive enhancer, with sigma1 receptor agonistic properties. Behav. Brain Res. 1997, 83, 221-224.
96. Maurice, T.; Phan, V.L.; Urani, A.; Guillemain, I. Differential involvement of the sigma(1) (sigma(1)) receptor in the anti-amnesic effect of neuroactive steroids, as demonstrated using an in vivo antisense strategy in the mouse. Br. J. Pharmacol. 2001, 134, 1731-1741.
97. Zheng, P. Neuroactive steroid regulation of neurotransmitter release in the CNS: Action, mechanism and possible significance. Prog. Neurobiol. 2009, 89, 134-152.
98. Romieu, P.; Martin-Fardon, R.; Maurice, T. Involvement of the sigma1 receptor in the cocaine-induced conditioned place preference. Neuroreport 2000, 11, 2885-2888.
99. Romieu, P.; Phan, V.L.; Martin-Fardon, R.; Maurice, T. Involvement of the sigma(1) receptor in cocaine-induced conditioned place preference: Possible dependence on dopamine uptake blockade. Neuropsychopharmacology 2002, 26, 444-455.
100. Martin-Fardon, R.; Maurice, T.; Aujla, H.; Bowen, W.D.; Weiss, F. Differential effects of sigma1 receptor blockade on self-administration and conditioned reinstatement motivated by cocaine vs natural reward. Neuropsychopharmacology 2007, 32, 1967-1973.
101. Tanda, G.; Pontieri, F.E.; Frau, R.; di Chiara, G. Contribution of blockade of the noradrenaline carrier to the increase of extracellular dopamine in the rat prefrontal cortex by amphetamine and cocaine. Eur. J. Neurosci. 1997, 9, 2077-2085.
102. Snoddy, A.M.; Tessel, R.E. Prazosin: Effect on psychomotor-stimulant cues and locomotor activity in mice. Eur. J. Pharmacol. 1985, 116, 221-228.
103. Monnet, F.P.; Blier, P.; Debonnel, G.; de Montigny, C. Modulation by sigma ligands of N-methyl-D-aspartate-induced [3H]noradrenaline release in the rat hippocampus: G-protein dependency. Naunyn Schmiedebergs Arch. Pharmacol. 1992, 346, 32-39.
104. Gonzalez-Alvear, G.M.; Werling, L.L. Sigma1 Receptors in rat striatum regulate NMDA-stimulated [3H]dopamine release via a presynaptic mechanism. Eur. J. Pharmacol. 1995, 294, 713-719.
105. Weatherspoon, J.K.; Gonzalez-Alvear, G.M.; Werling, L.L. Regulation of [3H]norepinephrine release from guinea pig hippocampus by sigma2 receptors. Eur. J. Pharmacol. 1997, 326, 133-138.
106. Monnet, F.P.; Mahe, V.; Robel, P.; Baulieu, E.E. Neurosteroids, via sigma receptors, modulate the [3H]norepinephrine release evoked by N-methyl-D-aspartate in the rat hippocampus. Proc. Natl. Acad. Sci. USA 1995, 92, 3774-3778.
107. Bermack, J.E.; Debonnel, G. Distinct modulatory roles of sigma receptor subtypes on glutamatergic responses in the dorsal hippocampus. Synapse 2005, 55, 37-44.
108. Ricaurte, G.A.; DeLanney, L.E.; Irwin, I.; Witkin, J.M.; Katz, J.L.; Langston, J.W. Evaluation of the neurotoxic potential of N,N-dimethylamphetamine: An illicit analog of methamphetamine. Brain Res. 1989, 490, 301-306.
109. Dong, L.; Zhu, Y.; Dong, Y.; Yang, J.; Zhao, Y.; Qi, Y.; Wu, P.; Zhu, Y.; Zheng, P. Neuroactive steroid dehydroepiandrosterone sulfate inhibits 5-hydroxytryptamine (5-HT)-evoked glutamate release via activation of sigma-1 receptors and then inhibition of 5-HT3 receptors in rat prelimbic cortex. J. Pharmacol. Exp. Ther. 2009, 330, 494-501.
110. Takahashi, S.; Horikomi, K.; Kato, T. MS-377, a novel selective sigma(1) receptor ligand, reverses phencyclidine-induced release of dopamine and serotonin in rat brain. Eur. J. Pharmacol. 2001, 427, 211-219.
111. Bermack, J.E.; Debonnel, G. Modulation of serotonergic neurotransmission by short- and long-term treatments with sigma ligands. Br. J. Pharmacol. 2001, 134, 691-699.
112. Seminerio, M.J.; Kaushal, N.; Shaikh, J.; Huber, J.D.; Coop, A.; Matsumoto, R.R. Sigma (sigma) Receptor Ligand, AC927 (N-Phenethylpiperidine Oxalate), Attenuates Methamphetamine-Induced Hyperthermia and Serotonin Damage in Mice. Pharmacol. Biochem. Behav. 2011, 98, 12-20.
113. Mtchedlishvili, Z.; Kapur, J. A presynaptic action of the neurosteroid pregnenolone sulfate on GABAergic synaptic transmission. Mol. Pharmacol. 2003, 64, 857-864.
114. Maurice, T.; Gregoire, C.; Espallergues, J. Neuro(active)steroids actions at the neuromodulatory sigma1 ([sigma]1) receptor: Biochemical and physiological evidences, consequences in neuroprotection. Pharmacol. Biochem. Behav. 2006, 84, 581-597.
115. Sharkey, J.; Glen, K.A.; Wolfe, S.; Kuhar, M.J. Cocaine binding at sigma receptors. Eur. J. Pharmacol. 1988, 149, 171-174.
116. Ritz, M.C.; George, F.R. Cocaine-induced seizures and lethality appear to be associated with distinct central nervous system binding sites. J. Pharmacol. Exp. Ther. 1993, 264, 1333-1343.
117. McCracken, K.A.; Bowen, W.D.; de Costa, B.R.; Matsumoto, R.R. Two novel sigma receptor ligands, BD1047 and LR172, attenuate cocaine-induced toxicity and locomotor activity. Eur. J. Pharmacol. 1999, 370, 225-232.
118. Matsumoto, R.R.; McCracken, K.A.; Friedman, M.J.; Pouw, B.; de Costa, B.R.; Bowen, W.D. Conformationally restricted analogs of BD1008 and an antisense oligodeoxynucleotide targeting sigma1 receptors produce anti-cocaine effects in mice. Eur. J. Pharmacol. 2001, 419, 163-174.
119. Menkel, M.; Terry, P.; Pontecorvo, M.; Katz, J.L.; Witkin, J.M. Selective sigma ligands block stimulant effects of cocaine. Eur. J. Pharmacol. 1991, 201, 251-252.
120. Chausmer, A.L.; Katz, J.L. The role of D2-like dopamine receptors in the locomotor stimulant effects of cocaine in mice. Psychopharmacology (Berl) 2001, 155, 69-77.
121. Okuyama, S.; Imagawa, Y.; Ogawa, S.; Araki, H.; Ajima, A.; Tanaka, M.; Muramatsu, M.; Nakazato, A.; Yamaguchi, K.; Yoshida, M., et al. NE-100, a novel sigma receptor ligand: In vivo tests. Life Sci. 1993, 53, PL285-PL290.
122. Matsumoto, R.R. Targeting sigma receptors: Novel medication development for drug abuse and addiction. Expert Rev. Clin. Pharmacol. 2009, 2, 351-358.
123. Ujike, H.; Tsuchida, K.; Akiyama, K.; Otsuki, S. Supersensitivity of sigma receptors after repeated administration of cocaine. Life Sci. 1992, 51, PL31-PL36.
124. Witkin, J.M.; Terry, P.; Menkel, M.; Hickey, P.; Pontecorvo, M.; Ferkany, J.; Katz, J.L. Effects of the selective sigma receptor ligand, 6-[6-(4-hydroxypiperidinyl)hexyloxy]-3-methylflavone (NPC 16377), on behavioral and toxic effects of cocaine. J. Pharmacol. Exp. Ther. 1993, 266, 473-482.
125. Takahashi, S.; Miwa, T.; Horikomi, K. Involvement of sigma 1 receptors in methamphetamine-induced behavioral sensitization in rats. Neurosci. Lett. 2000, 289, 21-24.
126. Okuyama, S.; Imagawa, Y.; Tomisawa, K. Behavioral evidence for modulation by sigma ligands of (+)MK-801-induced hyperlocomotion in monoamine-depleted mice. Neuropharmacology 1996, 35, 467-474.
127. Xu, X.; Domino, E.F. Cross-sensitization between phencyclidine and (-) but not (+) pentazocine. Pharmacol. Biochem. Behav. 1997, 56, 205-210.
128. Maurice, T.; Casalino, M.; Lacroix, M.; Romieu, P. Involvement of the sigma 1 receptor in the motivational effects of ethanol in mice. Pharmacol. Biochem. Behav. 2003, 74, 869-876.
129. Skuza, G.; Rogoz, Z. Antidepressant-like effect of PRE-084, a selective sigma1 receptor agonist, in Albino Swiss and C57BL/6J mice. Pharmacol. Rep. 2009, 61, 1179-1183.
130. Maj, J.; Rogoz, Z.; Skuza, G.; Mazela, H. Neuropharmacological profile of EMD 57445, a sigma receptor ligand with potential antipsychotic activity. Eur. J. Pharmacol. 1996, 315, 235-243.
131. Skuza, G. Effect of sigma ligands on the cocaine-induced convulsions in mice. Pol. J. Pharmacol. 1999, 51, 477-483.
132. Lever, J.R.; Gustafson, J.L.; Xu, R.; Allmon, R.L.; Lever, S.Z. Sigma1 and sigma2 receptor binding affinity and selectivity of SA4503 and fluoroethyl SA4503. Synapse 2006, 59, 350-358.
133. Matsuno, K.; Nakazawa, M.; Okamoto, K.; Kawashima, Y.; Mita, S. Binding properties of SA4503, a novel and selective sigma 1 receptor agonist. Eur. J. Pharmacol. 1996, 306, 271-279.
134. Rodvelt, K.R.; Lever, S.Z.; Lever, J.R.; Blount, L.R.; Fan, K.H.; Miller, D.K. SA 4503 attenuates cocaine-induced hyperactivity and enhances methamphetamine substitution for a cocaine discriminative stimulus. Pharmacol. Biochem. Behav. 2011, 97, 676-682.
135. Rodvelt, K.R.; Oelrichs, C.E.; Blount, L.R.; Fan, K.H.; Lever, S.Z.; Lever, J.R.; Miller, D.K. The sigma receptor agonist SA4503 both attenuates and enhances the effects of methamphetamine. Drug Alcohol Depend. 2011, 116, 203-210.
136. Holtzman, S.G. Discriminative Stimulu Effects of Drugs: Relationship to Potential for Abuse. In Testing and Evaluation of Drugs of Abuse. In Modern methods in pharmacology; Adler, M.W., Cowan, A., Eds.; Wiley-Liss: New York, NY, USA, 1990; Volume 6, pp. 193-210.
137. Witkin, J.M.; Nichols, D.E.; Terry, P.; Katz, J.L. Behavioral effects of selective dopaminergic compounds in rats discriminating cocaine injections. J. Pharmacol. Exp. Ther. 1991, 257, 706-713.
138. Holtzman, S.G. Discriminative stimulus effects of dextromethorphan in the rat. Psychopharmacology (Berl) 1994, 116, 249-254.
139. Gavend, M.; Mallaret, M.; Dematteis, M.; Baragatti, G. Discriminative stimulus properties of dextromethorphan in rats. Biomed. Pharmacother. 1995, 49, 456-464.
140. Steinfels, G.F.; Tam, S.W.; Cook, L. Discriminative stimulus properties of (+)-N-allylnormetazocine in the rat: Correlations with (+)-N-allylnormetazocine and phencyclidine receptor binding. Psychopharmacology (Berl) 1987, 91, 5-9.
141. Balster, R.L. Substitution and antagonism in rats trained to discriminate (+)-N-allylnormetazocine from saline. J. Pharmacol. Exp. Ther. 1989, 249, 749-756.
142. Singh, L.; Wong, E.H.; Kesingland, A.C.; Tricklebank, M.D. Evidence against an involvement of the haloperidol-sensitive sigma recognition site in the discriminative stimulus properties of (+)-N-allylnormetazocine ((+)-SKF 10,047). Br. J. Pharmacol. 1990, 99, 145-151.
143. Holtzman, S.G. Opioid- and phencyclidine-like discriminative effects of ditolylguanidine, a selective sigma ligand. J. Pharmacol. Exp. Ther. 1989, 248, 1054-1062.
144. Steinfels, G.F.; Alberici, G.P.; Tam, S.W.; Cook, L. Biochemical, behavioral, and electrophysiologic actions of the selective sigma receptor ligand (+)-pentazocine. Neuropsychopharmacology 1988, 1, 321-327.
145. Ukai, M.; Mori, E.; Kameyama, T. Modulatory effects of morphine, U-50488H and 1,3-di-(2-tolyl)guanidine on cocaine-like discriminative stimulus in the rat using two-choice discrete-trial avoidance paradigm. Methods Find Exp. Clin. Pharmacol. 1997, 19, 541-546.
146. Cohen, C.; Sanger, D.J. Effects of sigma ligands on the cocaine discriminative stimulus in rats. NIDA Res. Monogr. 1994, 153, 380.
147. Hiranita, T.; Soto, P.; Tanda, G.; Katz, J. Lack of cocaine-like discriminative-stimulus effects of σ receptor agonists in rats. Behav. Pharmacol. 2011, in press.
148. Colpaert, F.C.; Niemegeers, C.J.; Janssen, P.A. Discriminative stimulus properties of cocaine: Neuropharmacological characteristics as derived from stimulus generalization experiments. Pharmacol. Biochem. Behav. 1979, 10, 535-546.
149. Li, S.M.; Campbell, B.L.; Katz, J.L. Interactions of cocaine with dopamine uptake inhibitors or dopamine releasers in rats discriminating cocaine. J. Pharmacol. Exp. Ther. 2006, 317, 1088-1096.
150. Hundt, W.; Danysz, W.; Holter, S.M.; Spanagel, R. Ethanol and N-methyl-D-aspartate receptor complex interactions: A detailed drug discrimination study in the rat. Psychopharmacology (Berl) 1998, 135, 44-51.
151. Holtzman, S.G. Discriminative stimulus effects of buprenorphine in the rat. Psychopharmacology (Berl) 1997, 130, 292-299.
152. Tzschentke, T.M. Measuring reward with the conditioned place preference paradigm: A comprehensive review of drug effects, recent progress and new issues. Prog. Neurobiol. 1998, 56, 613-672.
153. Horan, B.; Gardner, E.L.; Dewey, S.L.; Brodie, J.D.; Ashby, C.R., Jr. The selective sigma(1) receptor agonist, 1-(3,4-dimethoxyphenethyl)-4-(phenylpropyl)piperazine (SA4503), blocks the acquisition of the conditioned place preference response to (-)-nicotine in rats. Eur. J. Pharmacol. 2001, 426, R1-R2.
154. Iwamoto, E.T. Place-conditioning properties of mu, kappa, and sigma opioid agonists. Alcohol Drug Res. 1985, 6, 327-339.
155. Romieu, P.; Martin-Fardon, R.; Bowen, W.D.; Maurice, T. Sigma 1 receptor-related neuroactive steroids modulate cocaine-induced reward. J. Neurosci. 2003, 23, 3572-3576.
156. Slifer, B.L.; Balster, R.L. Reinforcing properties of stereoisomers of the putative sigma agonists N-allylnormetazocine and cyclazocine in rhesus monkeys. J. Pharmacol. Exp. Ther. 1983, 225, 522-528.
157. Katz, J.L.; Higgins, S.T. The validity of the reinstatement model of craving and relapse to drug use. Psychopharmacology (Berl) 2003, 168, 21-30.
158. Hiranita, T.; Soto, P.L.; Newman, A.H.; Katz, J.L. Assessment of reinforcing effects of benztropine analogs and their effects on cocaine self-administration in rats: Comparisons with monoamine uptake inhibitors. J. Pharmacol. Exp. Ther. 2009, 329, 677-686.
159. Liu, Y.; Chen, G.D.; Lerner, M.R.; Brackett, D.J.; Matsumoto, R.R. Cocaine up-regulates Fra-2 and sigma-1 receptor gene and protein expression in brain regions involved in addiction and reward. J. Pharmacol. Exp. Ther. 2005, 314, 770-779.
160. Liu, Y.; Matsumoto, R.R. Alterations in fos-related antigen 2 and sigma1 receptor gene and protein expression are associated with the development of cocaine-induced behavioral sensitization: Time course and regional distribution studies. J. Pharmacol. Exp. Ther. 2008, 327, 187-195.
161. Stefanski, R.; Justinova, Z.; Hayashi, T.; Takebayashi, M.; Goldberg, S.R.; Su, T.P. Sigma1 receptor upregulation after chronic methamphetamine self-administration in rats: A study with yoked controls. Psychopharmacology (Berl) 2004, 175, 68-75.
162. Stefanski, R.; Ladenheim, B.; Lee, S.H.; Cadet, J.L.; Goldberg, S.R. Neuroadaptations in the dopaminergic system after active self-administration but not after passive administration of methamphetamine. Eur. J. Pharmacol. 1999, 371, 123-135.
163. Hayashi, T.; Justinova, Z.; Hayashi, E.; Cormaci, G.; Mori, T.; Tsai, S.Y.; Barnes, C.; Goldberg, S.R.; Su, T.P. Regulation of sigma-1 receptors and endoplasmic reticulum chaperones in the brain of methamphetamine self-administering rats. J. Pharmacol. Exp. Ther. 2010, 332, 1054-1063.
164. Ben-Ami, O.; Kinor, N.; Perelman, A.; Yadid, G. Dopamine-1 receptor agonist, but not cocaine, modulates sigma(1) gene expression in SVG cells. J. Mol. Neurosci. 2006, 29, 169-176.
165. Zhang, D.; Zhang, L.; Tang, Y.; Zhang, Q.; Lou, D.; Sharp, F.R.; Zhang, J.; Xu, M. Repeated cocaine administration induces gene expression changes through the dopamine D1 receptors. Neuropsychopharmacology 2005, 30, 1443-1454.